Koji Takahashi, PhD

Emraclidine as a Novel Positive Allosteric Modulator Targeting M4 Muscarinic Receptors: Results From a Phase 1b Trial in Patients With Schizophrenia

Abstract: Background: Emraclidine is a novel, highly selective, M4 muscarinic receptor positive allosteric modulator in development for treating schizophrenia. Here, we describe safety, t...

Koji Takahashi , PhD;

Rebecca Goodrich ;

01/19/2023

EMPOWERing the Next-Generation: A phase 2 Program to Evaluate Emraclidine, a Selective M4 Positive Allosteric Modulator (PAM), for the Treatment of Schizophrenia

Detailed study designs for the EMPOWER program will be presented. Primary outcome measure for EMPOWER 1 and 2 is change from baseline in PANSS total score at week 6. Other outcome measure...

Koji Takahashi , PhD;

10/26/2023